{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:23:39Z","timestamp":1791289419752,"version":"4.3.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejca.2015.12.020","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T20:56:01Z","timestamp":1454360161000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX"],"prefix":"10.1016","volume":"56","clinical-trial-number":[{"clinical-trial-number":"nct00578201","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"G\u00e9rard","family":"Lledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoist","family":"Chibaudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mineur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Artru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Blondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menouar Samir","family":"Abdiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jovenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Pozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.12.020_bib1","series-title":"Globocan 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10","author":"Ferlay","year":"2010"},{"key":"10.1016\/j.ejca.2015.12.020_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2015.12.020_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0142(19910101)67:1<91::AID-CNCR2820670118>3.0.CO;2-A","article-title":"Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma","volume":"67","author":"Yano","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.12.020_bib6","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2015.12.020_bib7","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","article-title":"Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"20","author":"Lorenzen","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2010.31.9715","article-title":"Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB\/II Trial (SAKK 75\/06)","volume":"29","author":"Ruhstaller","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/gut.23.12.1060","article-title":"Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy","volume":"23","author":"Ogilvie","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2015.12.020_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2015.12.020_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2015.12.020_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2015.12.020_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.bjc.6606093","article-title":"A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer","volume":"104","author":"De Vita","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.12.020_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/JTO.0b013e31824c7bed","article-title":"Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)","volume":"7","author":"Tomblyn","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib15","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/j.1349-7006.2012.02393.x","article-title":"Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma","volume":"103","author":"Chen","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2015.12.020_bib16","first-page":"4019","article-title":"A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer","volume":"32","author":"Hollander","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2015.12.020_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.3_suppl.lba6","article-title":"The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery","volume":"32","author":"Suntharalingam","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2006.01.009","article-title":"Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response","volume":"78","author":"Geh","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2015.12.020_bib23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijrobp.2010.10.023","article-title":"Esophageal cancer dose escalation using a simultaneous integrated boost technique","volume":"82","author":"Welsh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T16:30:49Z","timestamp":1537029049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915011764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":23,"alternative-id":["S0959804915011764"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}